검색
Transcode Therapeutics Inc
RNAZ관심 목록에 추가
4.750USD
-0.500-9.52%
종가 07-31 16:00（ET）시세는 15분 지연됩니다
3.96M시가총액
손실P/E TTM
자세한 내용은 Transcode Therapeutics Inc 회사
TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. It is defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis. The Company is also developing a portfolio of RNA therapeutic candidates to overcome delivery challenges and unlock access to novel genetic targets. Its preclinical programs include TTX-siPDL1 (siRNA modulator of PD-L1), TTX-RIGA (RNA agonist of RIG-I for innate immunity activation), and TTX-siMYC (siRNA inhibitor of c-MYC). Additionally, R&D efforts are exploring the combination of TTX-MC138 and seviprotimut-L technologies to enhance therapeutic impact.
Transcode Therapeutics Inc 정보
종목 코드 RNAZ
회사 이름Transcode Therapeutics Inc
상장일Apr 28, 2021
CEOCalais (Philippe P)
직원 수7
유형Ordinary Share
회계 연도 종료Apr 28
주소6 Liberty Square
도시BOSTON
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호02109
전화18573016857
웹사이트https://www.transcodetherapeutics.com/
종목 코드 RNAZ
상장일Apr 28, 2021
CEOCalais (Philippe P)
Transcode Therapeutics Inc의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Mr. Thomas A. (Tom) Fitzgerald
Mr. Thomas A. (Tom) Fitzgerald
Chief Financial Officer, Vice President, Director
Chief Financial Officer, Vice President, Director
3.00
--
Dr. Philippe P. Calais, Ph.D.
Dr. Philippe P. Calais, Ph.D.
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
2.00
--
Dr. Erik Manting, Ph.D.
Dr. Erik Manting, Ph.D.
Independent Director
Independent Director
--
--
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
--
--
Dr. Daniel Vlock
Dr. Daniel Vlock
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Elizabeth Czerepak
Ms. Elizabeth Czerepak
Independent Director
Independent Director
--
--
이름
이름/직위
직위
주식 보유
변동
Mr. Thomas A. (Tom) Fitzgerald
Mr. Thomas A. (Tom) Fitzgerald
Chief Financial Officer, Vice President, Director
Chief Financial Officer, Vice President, Director
3.00
--
Dr. Philippe P. Calais, Ph.D.
Dr. Philippe P. Calais, Ph.D.
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
2.00
--
Dr. Erik Manting, Ph.D.
Dr. Erik Manting, Ph.D.
Independent Director
Independent Director
--
--
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
--
--
Dr. Daniel Vlock
Dr. Daniel Vlock
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Elizabeth Czerepak
Ms. Elizabeth Czerepak
Independent Director
Independent Director
--
--
자주 묻는 질문
Transcode Therapeutics Inc의 상위 5대 주주는 누구인가요?
Transcode Therapeutics Inc의 상위 5대 주주는 다음과 같습니다: Mr. Thomas A. (Tom) Fitzgerald
Transcode Therapeutics Inc(RNAZ)의 주식을 보유한 기관은 몇 개입니까?
2026Q1 기준으로, Transcode Therapeutics Inc의 주식을 보유한 기관은 총 37곳이며, 이들이 보유한 주식의 총 가치는 약 77.85K로 전체 발행 주식의 8.49%를 차지합니다. 이는 2025Q4 대비 -42306.00 증가한 수치입니다.